But these funds performance avialable since 2007 only post 2008 crisis Central banks printed so much monies which expaned PE ratio to unsustainable level for QUALITY companies
Posts tagged Value Pickr
Wockhardt: an NiCE story (29-06-2024)
Excerpt from Chairman’s Speech at AGM, convened on June 28, 2024, at 11 am
- Over a span of 25 years, we dedicated substantial efforts to establish a global antibiotic research organisation.
- Fostered a culture of Research and Innovation, collaborating with more than 30 global organisations.
- Invested over US$ 500 million in discovering antibiotics to address unmet medical needs.
- Our diverse antibiotic portfolio tackles antimicrobial resistance across various classes, developed over 30-40 years, targeting infections in both hospital and community settings.
EMROK & EMROK O
- EMROK & EMROK O have treated more than 65,000 patients.
- Successfully concluded 4 new clinical studies covering bloodstream infections, bone and joint infections, community-acquired bacterial pneumonia, and infections in immunosuppressed patients.
- Completed New Drug Application (NDA) submissions in 10 Emerging Markets countries and aiming for 5-6 additional countries by Q2 of FY 2025.
- Anticipating substantial growth in the current year due to these expansions.
WCK 4873 (Nafithromycin), trademarked as MIQNAF
- MIQNAF (WCK 4873) offers an ultrashort, 3-day oral treatment for community-acquired bacterial pneumonia, achieving a 97% success rate.
- Current treatments face up to 60% resistance.
- Filed New Drug Application (NDA) with the Drug Controller General of India (DGCI) and anticipate commercial launch in India by the second half of FY25.
- Planning NDA filings in selected Emerging Markets and foreseeing strong sales in FY26.
WCK 5222 (Zidebactam/Cefepime), trademarked as ZAYNICH
- A groundbreaking new antibiotic developed by Wockhardt.
- This proprietary drug, designed to combat major superbugs, is the first of its kind discovered in the past 50 years.
- Currently in Global Phase 3 clinical trials.
- ZAYNICH was granted compassionate use approval by the DCGI for 30 critically ill patients unresponsive to existing antibiotics.
- Achieving a 100% success rate, ZAYNICH saved the lives of all recipients, with notable cases published in prestigious international journals.
- To date, ZAYNICH has saved over 30 lives, with DCGI approval secured for a small-scale clinical trial involving carbapenem-resistant patients in India.
- Pending completion by FY25, approval would enable ZAYNICH to become available in India, marking a significant milestone in its clinical deployment.
- The US FDA granted ‘Expanded Access IND’ approval for WCK 5222 (ZAYNICH) to treat a young cancer patient at the University of California Irvine School of Medicine, Orange County.
- Despite nine months of unresponsiveness to current US antibiotics, the patient showed significant improvement within four weeks of ZAYNICH administration.
- The treatment resulted in complete healing of large wounds and eradication of infections, allowing the patient to resume chemotherapy for ongoing cancer treatment.
- CLSI, a globally-recognized US body, has approved a susceptibility breakpoint of 64 mg/L for ZAYNICH.
- This breakpoint applies to a wide spectrum of Gram-negative pathogens resistant to multiple drugs.
- ZAYNICH demonstrates unprecedented effectiveness with its high bacteria kill power, crucial for extreme multi-drug resistant organisms.
- For the first time, a breakpoint of 64 mg/L covers the entire spectrum of 10-resistant Gram-negative pathogens, underscoring ZAYNICH’s clinical potency.
- Clinical trials under compassionate use show a 100% success rate in critically ill patients, affirming its safety and efficacy over 70 days.
- ZAYNICH’s achievement of the investigational breakpoint at a CLSI plenary session on June 24, 2024, marks a historic milestone, a source of pride for Wockhardt and India.
- Global Phase III clinical trials for ZAYNICH are anticipated to conclude by FY25.
- Plans include filing for regulatory approvals in the US, Europe, and other regions following trial completion.
- Global approval for ZAYNICH’s launch worldwide is expected in FY26.
- Strategically, we aim to maximize market value through a dual strategy: direct marketing in India and Emerging Markets, alongside licensing agreements with global pharmaceutical companies for US, Europe, and other developed regions.
Source: https://www.wockhardt.com/wp-content/uploads/2024/06/chairmans-agm-speech-2024.pdf
Garware Hi-Tech Films Ltd: A Hidden Consumer Story in the Polyester Film Industry (29-06-2024)
The speciality films portfolio mainly comprises Sun control films, shrink films, paint protection films and low oligomer products. The share of value-add products of the Company has increased from 48%
of overall revenues in FY17 to 80% as of FY23.
To support Garware Application Studios, we have launched a product, Titanium, which is top of the top rolls, but only given to GAS.
XPEL their competitor - has signaled headwinds but to that question management said they already did well for thei Qtr vs XPEL
Ambika Cotton Mills (29-06-2024)
Cotton Prices rose in 2022 because of higher demand for knits due to WFH around COVID and major upgrades of home textiles by US buyers. Post that, the textile mix should again go back to formal clothes / outer clothes - which are cotton, cotton mix or pure synthetic…
In short - the 2022 trend is not going to repeat itself. We may see cotton price increase once the demand from US picks up since that is where most of our garments, home textiles and knitwear is exported to.
Same holds for domestic demand. Barring Dollar, no other innerwear co or fashion clothing co is reporting double digit volume growth or 20%+ rev growth yet.
Ambika Cotton Mills (29-06-2024)
I did a linear regression of Cotton Yarn WPI monthly price data vis-a-vis monthly stock price of major listed cotton yarn players - It looks like Ambika’s stock price is the one that most closely follows the cotton yarn price
Company | CMP correlation with Cotton Yarn Price |
---|---|
AMBIKA | 60% |
VART | 49% |
Rajapalayam | 1% |
NITIN | 47% |
Now that we’ve established that cotton yarn price increase will also lead to increase in Ambika’s stock price, how do we establish that cotton yarn prices are rebounding back to previous peak?
I looked at the WPI data and it looks like 2022 was a major exception in terms of cotton yarn price increase. No other year has the cotton yarn prices have increased so much.
Honestly, cotton yarn prices had remained static for 8 years prior to 2020 irrespective of inflation.
Calendar Year | Index |
---|---|
2023 | 131.4 |
2022 | 154 |
2021 | 133.2 |
2020 | 111 |
2019 | 116.1 |
2018 | 115.5 |
2017 | 113.2 |
2016 | 108.4 |
2015 | 107.7 |
2014 | 117.5 |
2013 | 113.7 |
If anyone with experience in this sector could chime in? @sunilkumarca3101
Saregama India Ltd: India’s premier music publishing label (29-06-2024)
Very insightful podcast explaining the nuances of music distribution and monetization from both the global and Indian perspective.
Siddhartha Roy | The Music Podcast: @hungamamusicofficial Distribution, Monetization & Digital Ent.
Jupiter Wagons Ltd (previously CEBBCO) (29-06-2024)
Allotted 28,72,340 Convertible Warrants.
Virtuoso Optoelectronics Ltd – A promising micro Cap (29-06-2024)
Such co’s often dilute via qip to keep debt levels comfortable as this is a capex intensive business. That’s why the holding has come down
Bajaj Investment Holding Co (29-06-2024)
I have one question
Bajaj holding is trading at p/e of 13
Tata investment p/e is 82
Why is this difference is tata investment do different business
Virtuoso Optoelectronics Ltd – A promising micro Cap (29-06-2024)
The promoter has been consistently reducing their stake from 73.51% to now 56.88%. Anything to worry?